Pages

methadone and suboxone

First national clinical trial to investigate treatments for prescription opioid use disorder

December 14, 2017
The CRCHUM and the Canadian Research Initiative in Substance Misuse (CRISM), in collaboration with many Canadian partners, have launched the first-ever national clinical trial to study how patients respond to different treatments for prescription opioid use disorder, with the goal of improving treatment outcomes.
Lire la suite
Emmanuelle Brochiero and Émilie Maille

Cystic fibrosis: discovery of a key molecule for improving treatments

December 12, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have identified a promising solution to improving treatments offered to patients with cystic fibrosis.
Lire la suite
Anne Monette

Anne Monette and TimIOs Win International Competition for Focused Cancer Immunotherapy Research

December 11, 2017
Anne Monette, postdoctoral fellow emerging from the Réjean Lapointe Immuno-Oncology laboratory (CRCHUM, University of Montreal and Montreal Cancer Institute), is embarking on a ground-breaking research project to identify cancer immunotherapy responders. Anne is a member of team TimIOs, winners of the SITC Sparkathon – Emerging Leaders, Igniting Innovation competition held in August by the American Society for Immunotherapy of Cancer (SITC).
Lire la suite
John D. Rioux

Can genetics and genomics truly contribute to drug target identification and precision medicine?

December 8, 2017
On December 15th, 2017, the CRCHUM Conferences invites John D. Rioux, professor of medicine at University of Montreal and Montreal Heart Institute, CRC in Genetics and Genomic Medicine. During this conference he will focus on the inflammatory bowel diseases such as Crohn’s Disease and ulcerative colitis.
Lire la suite
Anne-Marie Mes-Masson

Anne-Marie Mes-Masson Appointed to the CRCHUM’s Management Team

December 1, 2017
The University of Montreal Hospital Research Centre (CRCHUM) has announced the appointment of Anne-Marie Mes-Masson as Associate Scientific Director of Basic and Translational Research.
Lire la suite
Lisa McKerracher

Developing a new drug for orphan CNS disorders: the path from benchside to clinic

December 1, 2017
On December 8th, 2017, the CRCHUM Conferences invites Lisa McKerracher, Founder and CEO, BioAxone BioSciences and Adjunct Professor, Department of Neurology and Neurosurgery at McGill University. During this conference she will review bed to bedside translation of their lead drug, a biologic drug to treat acute spinal cord injury.
Lire la suite
Jon McGavock

Pediatric Type 2 Diabetes in Canada - DREAMing of ways to Curb the Crisis

November 27, 2017
On December 1st, 2017, the CRCHUM Conferences invites Jon McGavock, Associate Professor, Department of Pediatrics, Faculty of Health Sciences, University of Manitoba. He will discuss during his talk the current state of science with regards to prevent and management of type 2 diabetes and it’s complications and examine the translational work conducted.
Lire la suite
Core Facilities team

Core Facilities and Services Round-Table Meeting

November 23, 2017
The CRCHUM’s core facilities and services teams held their first annual Round-Table Meeting on November 9th. It was attended by some 60 technical managers, scientists and employees working in the core facilities and services, including the animal facility and the Institutional Animal Protection Committee (CIPA).
Lire la suite
Bernard Courtieu

From research to routine clinical practice: Bio-informatic tools are permitting the use of large scale sequencing

November 20, 2017
On November 27th, 2017, the CRCHUM Conferences invites Bernard Courtieu, Chairman and Chief Executive Officer at IntegraGen. He will discuss, recent progress in bio-informatics & genomic interpretation software tools.
Lire la suite
Alex Parker and Pierre Drapeau

Discovery of a promising medication for amyotrophic lateral sclerosis (ALS)

November 16, 2017
Researchers from the CRCHUM and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
Lire la suite

Pages